Loading stock data…
XFOR
$3.85+0.14 (+3.77%)
After Hours$3.85+0.00 (+0.00%)· Last close Jun 9
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
X4 Pharmaceuticals, Inc. in the Healthcare sector is trading at $3.85. Wall Street consensus targets $11.75 (4 analysts), implying a +205.2% move over the next 12 months. The stock is currently 20% below its 52-week high of $4.83, remaining 2.4% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +205.2% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$3.85
Potential Downside
0%
Whystock Fair Value$3.85
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus4 analysts
Mean target$11.75+205.2%
Range$10.00 – $13.00
Fundamentals
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective a...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-59.20%
Volume
Today's trading volume
433,778
Recent News
How The X4 Pharmaceuticals (XFOR) Story Is Shifting With Mavorixafor And New EU Progress
X4 Pharmaceuticals has seen its modeled fair value price target move from US$8.00 to US$11.67, a sizable uplift that puts more focus on what the current share price is really discounting. Analysts are tying this change closely to expectations around mavorixafor in WHIM syndrome and primary chronic neutropenia, and to how much of that story is already reflected in the stock. As you read on, you will see how different analysts are framing this shift and what to watch as the narrative...
Bears are Losing Control Over X4 Pharmaceuticals (XFOR), Here's Why It's a 'Buy' Now
X4 Pharmaceuticals (XFOR) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
X4 Pharmaceuticals (XFOR) Upgraded to Buy: Here's What You Should Know
X4 Pharmaceuticals (XFOR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Here is Why X4 Pharmaceuticals (XFOR) is Among the Unrivaled Penny Stocks to Buy Now
With a stock price of $4.41, X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) is among the 10 Unrivaled Penny Stocks to Buy Now. X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) reported first-quarter revenue of $2.71 million on May 6, compared with analyst consensus estimates of $3.2 million. Management stated that its top priority remains the execution and enrollment of the pivotal Phase 3 […]
X4 Pharmaceuticals (XFOR) Reports Q1 Loss, Lags Revenue Estimates
X4 Pharmaceuticals (XFOR) delivered earnings and revenue surprises of +17.95% and -33.14%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?